The long-range goal of this Program Project is to develop vaccine strategies against mucosal SIV (and HIV in the future) transmission, with a special focus on identifying local and systemic mechanisms leading to protective B cell development and antibody production. The objectives for the Primate Core are to provide the experimental animals and support services needed to facilitate the efficient completion of the aims outlined in Project 1, 2, 3 and 4. This will include the provision of retrovirus-free adult female rhesus macaques from the Yerkes rhesus macaque breeding colonies;immunizations using the various immunization platforms (Projects 1 and 2) sample collections (for all projects) and repeated low dose vaginal challenges with SIVsmE660. The Primate Core tasks also include daily monitoring ofthe experimental animals;periodic physical examinations with blood collections for immunologic and virologic evaluations and procurement/shipment of samples to the Program Project investigators;the performance of CBCs and laboratory analyses as needed;Perform euthanasia with sample collection and processing for Projects 3 and 4;and the performance of a basic gross and histologic necropsy evaluations of all experimental animals that die or are sacrificed during the course of this study. Provision of these resources and support services will facilitate the development and testing of novel AIDS vaccine concepts proposed in this Program Project. The Primate Core will play a key role in the development of a vaccine to prevent mucosal transmission and pathogenicity of SIV and HIV and the determination Of correlates of such protection. Vaccine efficacy will be evaluated by its ability to 1) prevent acquisition of infection (sterilizing immunity) or 2) significant control of viremia post-challenge and preservation of protective immune responses.
This program will expand 2 promising SIV vaccine platforms as a preclinical model for an efficient HIV vaccine. In addition the experimental design ofthe primate experiment will also allow for detailed investigations into the mechanisms that contribute to this protection versus those that do not. To this end, the primate core will provide state ofthe art support in the design and conduct of primate vaccine experiments.
|Yang, Rendong; Bai, Yun; Qin, Zhaohui et al. (2014) EgoNet: identification of human disease ego-network modules. BMC Genomics 15:314|
|Derdeyn, Cynthia A; Moore, Penny L; Morris, Lynn (2014) Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS 9:210-6|
|Basu, Debby; Xiao, Peng; Ende, Zachary et al. (2014) Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection. Virology 462-463:295-8|
|Magri, Giuliana; Miyajima, Michio; Bascones, Sabrina et al. (2014) Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. Nat Immunol 15:354-64|
|Yu, Tianwei; Jones, Dean P (2014) Improving peak detection in high-resolution LC/MS metabolomics data using preexisting knowledge and machine learning approach. Bioinformatics 30:2941-8|
|Li, Shuzhao; Rouphael, Nadine; Duraisingham, Sai et al. (2014) Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 15:195-204|
|Romberg, Neil; Chamberlain, Nicolas; Saadoun, David et al. (2013) CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest 123:4283-93|
|Li, Shuzhao; Nakaya, Helder I; Kazmin, Dmitri A et al. (2013) Systems biological approaches to measure and understand vaccine immunity in humans. Semin Immunol 25:209-18|
|Pulendran, Bali; Oh, Jason Z; Nakaya, Helder I et al. (2013) Immunity to viruses: learning from successful human vaccines. Immunol Rev 255:243-55|
|Cerutti, Andrea; Cols, Montserrat; Puga, Irene (2013) Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 13:118-32|
Showing the most recent 10 out of 20 publications